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Abstract. Relationship between the levels of MHC class 1 antigen expressed on tumour 
cells and their susceptibility to allogenic and xenogenic NK cells was investigated. Mouse 
and human natural killer-resistance inducing factor (NK-RIF) preparations were used for 
augmenting/inducing MHC 1 antigen expression on murine YAC and human K562 tumour 
cells, respectively YAC cells with augmented MHC I antigen expression became relatively 
resistant to lysis by murine NK cells but not to rat NK cells. Similarly, induction of MHC 
I antigens on K562 cells reduced their susceptibility to human NK cells but not to monkey 
NK cells. These results indicate that the inverse correlation of MHC I antigen expression 
and NK susceptibility does not hold true for xenogenic pairs of NK effector and target 
cells. 
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1. Introduction 
 
Unlike cytotoxic Τ cells, target cell lysis mediated by NK effector cells is not 
restricted by MHC class I antigens (Herberman and Ortaldo 1981). MHC antigens 
may nonetheless play an important role in determining the NK susceptibility of 
tumour cells. An inverse correlation between the levels of MHC I antigens on 
target cells and their NK-susceptibility has been shown (Harel-Beilan et al 1986; 
Storkus et al 1987; Welsh et al 1981). Augmentation of MHC class I antigens 
induced by cytokines (Welsh et al 1981; Piontek et al 1985; Saxena et al 1988), 
in vivo passage of tumour cells (Taniguchi et al 1985; Karre et al 1986) or 
transfection with MHC class I genes (Storkus et al 1989), have been shown to 
depress NK-susceptibility of target. In addition, certain mutants with depressed or 
no expression of MHC I antigens show an increased susceptibility to NK lysis 
(Ljunggren and Karre 1985). This inverse relationship however does not always 
hold (Gorelik et al 1988; Nishimura et al 1988; Sarin et al 1994). 
While NK effector-target interaction per se is not restricted by MHC antigens, 
it is not very clear if the inverse correlation of MHC I antigen expression and 
NK susceptibility, is influenced by qualitative disparities at MHC loci on NK 
effector and target cells. Allogenic differences on NK and target cells do not appear 
to be important in this regard since enhanced MHC expression is known to render 
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targets NK resistance irrespective of the MHC allotypes of the two cell populations. 
In the present study we have investigated the MHC and NK susceptibility relationship 
using xenogenic effector-target cell combinations. Our results suggest that NK lysis 
may not be influenced by enhanced MHC expression on xenogenic targets. 
 
 
2. Materials and methods 
 
2.1 Tumour cells 
 
YAC (murine lymphoma) and K562 (human erythromyeloid leukemia) cell lines 
were propagated in culture in RPMI-1640 supplemented with 10% FCS, 2 × 10-5 Μ 
2-mercaptoethanol, 300 µg/ml glutamine and 60 µg/ml gentamicin (complete medium). 
 
2.2 Effector cells 
 
Mouse and rat spleen cells were obtained by gentle teasing of spleens in complete 
medium as described before (Saxena and Adler 1979). Mononuclear cells from 
Rheses monkey peripheral blood were obtained by centrifugation over Ficoll-Hypaque 
gradients as described elsewhere (Saxena et al 1980). Spleen or peripheral blood 
derived mononuclear cells were used as effector cells without further fractionation. 
 
2.3 Up-regulation of MHC class I antigens 
 
Natural killer-resistance inducing factor (NK-RIF) preparations were used for boosting 
the expression of class I MHC antigens on target cells (Saxena et al 1989, 1992). 
Starting materials for partial purification of mouse and human NK-RIF preparations 
were the culture supernatants from Concanavalin-A activated mouse spleen cells or 
human peripheral blood mononuclear cells, respectively. Cell preparations (5 × 106/ml 
in complete medium containing 2% instead of 10% FCS) were cultured with 5 µg/ml 
of Concanavalin-A, for 2 days and culture supernatants were obtained by 
centrifugation. NK-RIF preparations from both murine and human sources were 
isolated by the method described for rat NK-RIF (Saxena 1987; Saxena et al 1988). 
Briefly, culture supernatants were subjected to ammonium sulphate precipitation 
step (80% saturation). Precipitated material was pelleted, dissolved in water and 
dialyzed extensively for two days against 0·2 Μ glycine-HCl buffer pH 2·0, to 
deactivate gamma interferon. Resulting material was fractionated on Sephadex G-100 
columns and the NK-RIF peak i.e., fractions which induced augmentation of MHC I 
antigen expression on YAC (for mouse NK-RIF) or K562 (for human NK-RIF) 
tumour cells, were pooled and concentrated on Amicon membrane filters with 
5 kDa cut off point. NK-RIF preparations used in this study had no IFN activity 
as assessed by biological and immunoassays, in which NIH reference IFN preparation 
was used as standard. 
 
2.4 Staining tumour cells for MHC I antigens 
 
Control and NK-RIF treated tumour cells were incubated (105/tube for 20 min at 
4°C), with 50 µl of hybridoma supernatants reactive to MHC I antigens. For YAC 
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cells, a mixture of supernatants from hybridoma HB-13 secreting anti-H-2Kk antibody 
and hybridoma HB-102 secreting anti-H-2Dd antibodies, was used whereas for K562 
cells hybridoma secreting an antibody reactive to a nonpolymorphic determinant on 
class I HLA antigens (HB-95), was used. All hybridomas were obtained from 
ATCC. Cells were washed twice with PBS and were suspended in 0·1 ml of a 1 : 20 
diluted rabbit anti mouse Ig-FITC antibody preparation. After a 15 min incubation 
at 4°C, cells were washed and fixed in paraformaldehyde. For background nonspecific 
staining of control or NK-RIF treated tumour cells, the first step of treatment with 
anti-MHC I antibody containing hybridoma supernatants was omitted, and the cells 
were treated with the second antibody-FITC preparation alone. Cells were analysed 
on a Beckton Dickinson FACScan analyser. Tumour cells treated with second 
antibody alone were first run on the flowcytometer to fix the fluorescence gate 
above which cells would be considered to have specific staining for MHC I antigens. 
 
2.5 Chromium release assay of cytotoxicity 
 
Labelling of tumour cells and chromium release assay of cytotoxicity was performed 
as described before (Sarin et al 1989). 
 
3. Results 
 
3.1 Effect of NK-RIF preparations on MHC I antigen expression on YAC and 
K562 cells 
 
We have previously described a novel factor (NK-RIF), released by mitogen activated 
rat spleen cells, which induced a marked augmentation in MHC I antigen expression 
in YAC tumour cells and an attendant resistance to lysis by murine NK cells 
(Saxena et al 1988, 1991, 1992). NK-RIF preparations with similar biological 
properties have recently been partially purified from murine and human sources 
(Saxena et al 1991, 1992). Effects of mouse and human NK-RIF preparations on 
the MHC I antigen expression on YAC and K562 cells respectively, has been 
shown in figure 1. These results show that NK-RIF preparations induced a dose 
dependent increase in the expression of MHC I antigens on tumour cells. 
 
3.2 Susceptibility of control and NK-RIF treated target cells to lysis by 
allogenic and xenogenic NK cells 
 
Lysis of control and NK-RIF treated YAC cells by mouse and rat NK cells was 
examined at several effector to target cell (E/T) ratios. Results of two representative 
experiments are shown in figure 2. A significant decline in the NK susceptibility 
of YAC cells was seen if mouse spleen cells were used as effectors. Control as 
well as NK-RIF treated YAC cells were however killed equally well by rat spleen 
effector cells. Similar experiments were done with control (MHC I negative) and 
human NK-RIF treated K562 target cells. Results of two representative experiments 
given in figure 3 clearly show that NK-RIF treated K562 cells were lysed poorly 
by human NK cells. NK-RIF treated K562 cells were not found to have acquired 
any resistance to lysis by NK cells in monkey peripheral blood. In fact, NK-RIF 
treated K562 cells appeared to be lysed better by monkey NK cells. 
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Figure 1. Effect of NK-RIF preparations on the expression of MHC class I antigens on 
K562 and YAC tumour cell lines. Tumour cells were seeded at a concentration of 5 × 104/ml 
in complete medium, with various given concentrations of NK-RIF (abbreviated as RIF in 
figure), ranging from 0 to 5% V/V. Human NK-RIF was used with K562 cell line and 
mouse NK-RIF was used with YAC cells. After two days of culture, tumour cells were 
washed and stained for class I MHC antigens by the procedure given in methods. Results 
of flowcytometric analysis of cells are given. Vertical line in each panel represents the 
gate set-with cells stained with second antibody only (non specific stain). 
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Figure 2. Lysis of control and NK-RIF treated YAC cells to rat and mouse NK cells. 
YAC tumour cells were cultured with (●) or without (О) 5% V/V of a mouse NK-RIF 
preparation (representing a final concentration of l0µg protein/ml) for two days. Cells 
were washed, labelled with chromium and used as targets in a 4h assay of cytotoxicity 
using mouse or rat spleen cells as effectors. Results of two experiments are shown (top 
and bottom panels). Each point represents mean lysis obtained in three replicate assay 
wells. 
 
4. Discussion 
 
For K562 and YAC tumour cells, an inverse correlation between class I MHC 
expression levels and susceptibility to allogenic NK effector cells, is well established 
(Ljunggren and Karre 1990; Storkus and Dawson 1991). In the present study, we 
have demonstrated that enhanced levels of class I MHC antigens on these tumour 
cell lines lowers their susceptibility to allogenic but not to xenogenic NK effector 
cells. A soluble factor purified from the culture supernatants of activated mouse 
spleen cells or human peripheral blood mononuclear cells, which is known to be 
a potent agent for enhancing the expression of class I MHC antigens on tumour 
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Figure 3. Lysis of control and NK-RIF treated K562 cells to human and monkey NK 
cells. K562 tumour cells were cultured with (●) or without (О) 5% V/V of a human 
NK-RIF preparation (representing a final concentration of 5 µg protein/ml) preparation for 
two days. Cells were washed, labelled with chromium and used as targets in a 4h assay 
of cytotoxicity, using human or monkey peripheral blood mononuclear cells as effectors. 
Results of two representative experiments have been shown (top and bottom panels). Each 
point represents mean lysis obtained in three replicate assay wells. Error bars have been 
omitted because variations amongst replicates were very low, being in absolute terms, less 
than 2% target lysis. 
 
cell lines, was used for upregulating the expression of class I MHC antigens on 
these tumour cell lines. The factor called NK-RIF is a 12 kDa protein (rat NK-RIF), 
distinct from IFN and IL2, which induces NK but not CTL resistance in several 
tumour cell lines (Saxena et al 1988, 1992). NK-RIF treatment of tumour cells 
did not alter their ability to form conjugates with the effector cells (Saxena et al 
1988). 
While the mechanism of MHC I antigen related changes in NK susceptibility of 
target cells, is not clear, two hypotheses have been proposed to explain this 
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relationship (Ljunggren and Karre 1990). First hypothesis envisages a negative 
down-regulatory signal sent by class I MHC antigens to NK effector cells, and the 
second one postulates an interference by MHC I molecules in the target structure 
recognition by NK cells (Ljunggren and Karre 1990). The first hypothesis has 
received support from recent identification of a class of molecules (Ly 49 family) 
expressed on a subpopulation of NK effector cells, which may act as receptors for 
specific alleles of class I MHC antigens (e.g., Dd antigens for Ly 49 bearing subset 
of C57B1/6 NK cell), and appear to send an inhibitory signal to NK cells (Karlhofer 
et al 1992; Yokoyama and Seaman 1993). It should however be noted that Ly 49 
mediated down regulation of NK cells is “global” in nature and Dd allele bearing 
targets are not lysed by Ly 49 bearing NK cells either directly or through ADCC, 
reverse-ADCC and LDCC routes. YAC cells which express Dd allele are however 
an exception to this rule (Yokoyama and Seaman 1993). In the human system, a 
new set of molecules (p58) expressed on NK cells have been identified which 
appear to have a role similar to Ly 49 antigens on murine NK cells (Moretta et 
al 1993). Human analogues of p58 however show no structural homology with the 
Ly 49 antigens (Moretta et al 1993). Molecules on NK cells which are specifically 
involved in down regulation of NK cell activity in response to MHC I alleles on 
YAC and K562 target cells, are not known at present. Moreover, our recent data 
suggests that the target interference model rather than the down-regulatory signal 
model, may explain the lower NK susceptibility of MHC I upregulated YAC and 
K562 cells (Haridas and Saxena 1995a,b). Irrespective of the mechanism of protection 
of MHC I upregulated YAC and K562 tumour cells, our results indicate that 
xenogenic effector NK cells do not appear to be sensitive to changes in the 
expression of MHC I antigens on the tumour cells used by us. This might be due 
to two possible reasons. Firstly, it is possible that the MHC I sensing molecules 
on the rat and monkey NK cells do not sense MHC I molecules expressed on 
mouse (YAC) and human (K562) target cells respectively. Alternatively, it is 
possible that allogenic and xenogenic NK effector cells recognize different target 
structures (TS) on YAC and K562 target cells and the TS recognized by allogenic 
but not the xenogenic NK cells, are subject to interference by target MHC I 
molecules. Further clarification of the mechanisms involved would require the 
identification of MHC sensing molecules on rat and monkey NK cells and the TS 
on YAC and K562 targets recognized by allogenic and xenogenic NK cells. 
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